Business Description
Cyxone AB
ISIN : SE0007815428
Compare
Compare
Traded in other countries / regions
CYXO.Sweden4CX.Germany IPO Date
2016-06-07Description
Cyxone AB is a clinical biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The product candidates of the company include T20K and Rabeximod.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.37 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 36.9 | |||||
| 3-Year EPS without NRI Growth Rate | 39.1 | |||||
| 3-Year FCF Growth Rate | 30.5 | |||||
| 3-Year Book Growth Rate | -45.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.22 | |||||
| 9-Day RSI | 40.28 | |||||
| 14-Day RSI | 39.91 | |||||
| 6-1 Month Momentum % | -44.18 | |||||
| 12-1 Month Momentum % | -74.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.02 | |||||
| Quick Ratio | 2.02 | |||||
| Cash Ratio | 1.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -53.4 | |||||
| Shareholder Yield % | 4.68 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -65.37 | |||||
| ROA % | -57.51 | |||||
| ROIC % | -71.91 | |||||
| 3-Year ROIIC % | 255.5 | |||||
| ROC (Joel Greenblatt) % | -2002.99 | |||||
| ROCE % | -64.97 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.31 | |||||
| Price-to-Tangible-Book | 1.95 | |||||
| EV-to-EBIT | -0.4 | |||||
| EV-to-Forward-EBIT | -0.03 | |||||
| EV-to-EBITDA | -0.45 | |||||
| EV-to-Forward-EBITDA | -0.03 | |||||
| EV-to-FCF | -0.4 | |||||
| Price-to-Net-Current-Asset-Value | 3.9 | |||||
| Price-to-Net-Cash | 3.9 | |||||
| Earnings Yield (Greenblatt) % | -248.23 | |||||
| FCF Yield % | -155.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cyxone AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -0.137 | ||
| Beta | 0.11 | ||
| Volatility % | 73.47 | ||
| 14-Day RSI | 39.91 | ||
| 14-Day ATR (kr) | 0.003253 | ||
| 20-Day SMA (kr) | 0.0402 | ||
| 12-1 Month Momentum % | -74.42 | ||
| 52-Week Range (kr) | 0.0375 - 0.177674 | ||
| Shares Outstanding (Mil) | 375.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cyxone AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cyxone AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cyxone AB Frequently Asked Questions
What is Cyxone AB(OSTO:CYXO)'s stock price today?
The current price of OSTO:CYXO is kr0.04. The 52 week high of OSTO:CYXO is kr0.18 and 52 week low is kr0.04.
When is next earnings date of Cyxone AB(OSTO:CYXO)?
The next earnings date of Cyxone AB(OSTO:CYXO) is 2024-11-07.
Does Cyxone AB(OSTO:CYXO) pay dividends? If so, how much?
Cyxone AB(OSTO:CYXO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers